European Crohn's and Colitis Organisation Congress 2016

In this review:

Ustekinumab for moderate-severe refractory CD
Multi-donor FMT for UC
Adalimumab monotherapy vs combination with azathioprine for CD
Mercaptopurine for CD recurrence following surgical resection
Risk factors for colorectal neoplasia in UC
Anti-TNFs and morbidity after surgery for ileocolonic CD
Drug-concentration vs symptom-driven infliximab dose escalation
Nutritional optimisation of pre-surgical CD patients
Prognostic significance of faecal calprotectin in IBD
A consistent approach to postoperative CD care
Rapid point-of-care assay for infliximab quantification
Infliximab trough levels in capillary fingerstick blood
BÜHLMANN Quantum Blue® infliximab point-of-care assay

Please login below to download this issue (PDF)